We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
For the quarter ended September 2023, Novartis (NVS - Free Report) reported revenue of $11.78 billion, down 6.1% over the same period last year. EPS came in at $1.74, compared to $1.58 in the year-ago quarter.
The reported revenue represents a surprise of -2.20% over the Zacks Consensus Estimate of $12.05 billion. With the consensus EPS estimate being $1.70, the EPS surprise was +2.35%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Hematology- Tasigna - Rest of the world: $243 million versus the two-analyst average estimate of $229.25 million. The reported number represents a year-over-year change of -4.7%.
Revenues- Established Brands- Exforge Group - US: $3 million versus $4.77 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -40% change.
Revenues- Hematology- Promacta/Revolade - Rest of the world: $262 million compared to the $253.40 million average estimate based on two analysts. The reported number represents a change of +9.6% year over year.
Revenues- Neuroscience- Gilenya - Rest of the world: $150 million versus the two-analyst average estimate of $149.04 million. The reported number represents a year-over-year change of -17.1%.
Revenues- Hematology- Kymriah - Total: $124 million versus $134.43 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
Revenues- Established Brands- Exforge Group - Total: $187 million compared to the $170.80 million average estimate based on three analysts. The reported number represents a change of +1.1% year over year.
Revenues- Other Promoted Brands- Lucentis - Total: $363 million versus $360.50 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -20.2% change.
Revenues- Immunology- Xolair - Total: $369 million versus the three-analyst average estimate of $353.52 million. The reported number represents a year-over-year change of +14.6%.
Revenues- Established Brands- Gleevec/Glivec - Total: $144 million versus the three-analyst average estimate of $137.93 million. The reported number represents a year-over-year change of -19.1%.
Revenues- Established Brands- Sandostatin - Total: $338 million versus $312.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change.
Revenues- Hematology- Jakavi - Total: $427 million versus $435.52 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
Revenues- Immunology- Ilaris - Total: $335 million versus $303.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +23.2% change.
Shares of Novartis have returned -7% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended September 2023, Novartis (NVS - Free Report) reported revenue of $11.78 billion, down 6.1% over the same period last year. EPS came in at $1.74, compared to $1.58 in the year-ago quarter.
The reported revenue represents a surprise of -2.20% over the Zacks Consensus Estimate of $12.05 billion. With the consensus EPS estimate being $1.70, the EPS surprise was +2.35%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Hematology- Tasigna - Rest of the world: $243 million versus the two-analyst average estimate of $229.25 million. The reported number represents a year-over-year change of -4.7%.
- Revenues- Established Brands- Exforge Group - US: $3 million versus $4.77 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -40% change.
- Revenues- Hematology- Promacta/Revolade - Rest of the world: $262 million compared to the $253.40 million average estimate based on two analysts. The reported number represents a change of +9.6% year over year.
- Revenues- Neuroscience- Gilenya - Rest of the world: $150 million versus the two-analyst average estimate of $149.04 million. The reported number represents a year-over-year change of -17.1%.
- Revenues- Hematology- Kymriah - Total: $124 million versus $134.43 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
- Revenues- Established Brands- Exforge Group - Total: $187 million compared to the $170.80 million average estimate based on three analysts. The reported number represents a change of +1.1% year over year.
- Revenues- Other Promoted Brands- Lucentis - Total: $363 million versus $360.50 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -20.2% change.
- Revenues- Immunology- Xolair - Total: $369 million versus the three-analyst average estimate of $353.52 million. The reported number represents a year-over-year change of +14.6%.
- Revenues- Established Brands- Gleevec/Glivec - Total: $144 million versus the three-analyst average estimate of $137.93 million. The reported number represents a year-over-year change of -19.1%.
- Revenues- Established Brands- Sandostatin - Total: $338 million versus $312.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change.
- Revenues- Hematology- Jakavi - Total: $427 million versus $435.52 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
- Revenues- Immunology- Ilaris - Total: $335 million versus $303.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +23.2% change.
View all Key Company Metrics for Novartis here>>>Shares of Novartis have returned -7% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.